NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Status Active, not recruiting

Clinical Trial Summary

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

Clinical Trial Description

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. An adult phase 1 study established an RP2D of 100mg QD for lorlatinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2). Lorlatinib will be administered orally via tablets or via oral dispersion if patient is unable to swallow tablets whole All patients will participate in mandatory pharmacokinetic testing. ;

Study Design

Related Conditions & MeSH terms

Neuroblastoma

Clinical Trial Details

NCT number	NCT03107988
Study type	Interventional
Source	New Approaches to Neuroblastoma Therapy Consortium
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	September 5, 2017
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00492167` - Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma	Phase 1
Completed	`NCT04474678` - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")	N/A
Terminated	`NCT00801931` - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders	Phase 1/Phase 2
Recruiting	`NCT04253015` - A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
Terminated	`NCT00788125` - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT02933333` - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Phase 4
Recruiting	`NCT00588068` - Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Recruiting	`NCT04301843` - Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma	Phase 2
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT04040088` - An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors	Early Phase 1
Recruiting	`NCT06057948` - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma	Phase 2
Not yet recruiting	`NCT06335745` - PediCARE Health Equity Intervention in High-Risk Neuroblastoma	N/A
Recruiting	`NCT02559778` - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	Phase 2
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Recruiting	`NCT02245997` - Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma	N/A
Not yet recruiting	`NCT01156350` - Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma	Phase 2
Active, not recruiting	`NCT01192555` - Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma	Phase 1/Phase 2
Completed	`NCT01222780` - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer	Phase 1
Completed	`NCT01048892` - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Phase 1